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Background: Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had
been developed through empirical approaches without detailed understanding of the molecular mechanisms
involved. That approach changed with the introduction of biologic therapeutics at the end of the 20th century and
by the recent development of small-molecule inhibitors of intracellular signal transduction pathways. Here we compare
and discuss the advantages and disadvantages of those two groups of targeted anti-inflammatory therapeutics.
Discussion: TNF-blocking biologic agents were introduced into the therapy of rheumatoid arthritis and other
autoimmune and inflammatory diseases in the late 1990s. Further biologic agents targeting cytokine networks
or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy. During
the last few years, another wave of novel discoveries led to the development of a new class of small molecule
anti-inflammatory compounds targeting intracellular signal transduction molecules, such as tyrosine kinases. In
all those cases, the specific targets of the drugs are well defined and significant knowledge about their role in
the disease pathomechanism is available, qualifying them for being targeted therapeutics for inflammatory
rheumatic diseases. While both groups of targeted therapeutics offer significant clinical benefit, they clearly
differ in several aspects, such as the localization of their targets, their route of administration and target
specificity, as well as technical details such as manufacturing procedures and cost basis. In this debate paper, we
compare the advantages and disadvantages of the two different approaches, aiming to shed light on the
possible future of targeted therapies.
Summary: Biologic therapeutics and small-molecule inhibitors both have significant advantages and disadvantages in
the therapy of rheumatic diseases. The future of targeted therapies is one of the most exciting questions of current
rheumatology research and therapy.
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TofacitinibBackground
Inflammatory rheumatic diseases such as rheumatoid
arthritis (RA) or systemic lupus erythematosus (SLE) are
severe and chronic diseases that affect a significant
proportion of the population, cause deterioration of
the quality of life and place a major burden on health
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2014witnessed significant improvement in the therapy of these
diseases. However, there is an ongoing need for the devel-
opment of newer, more efficient and more cost-effective
therapeutic applications. The aim of this paper is to com-
pare the benefits and drawbacks of two of the recent
directions of targeted therapies in rheumatology: biologic
therapeutics and small molecule inhibitors.
Steroids and non-steroidal anti-inflammatory drugs
were introduced into the therapy of inflammatory
rheumatic diseases around the middle of the 20th cen-
tury (Figure 1) and provided symptomatic improvement
and pain relief. However, they had significant side effects
and, maybe more importantly, they failed to prevent dis-
ease progression and the development of a debilitatingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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1988 Methotrexate for treating RA
1998 Infliximab for Crohn’s disease
1998 Etanercept for RA
2006 Rituximab for RA
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Figure 1 Timeline of rheumatoid arthritis research and therapy. RA, rheumatoid arthritis; CML, chronic myelogenous leukemia.
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of aminopterin antimetabolites led to the introduction
of the chemotherapeutic agent methotrexate to the therapy
of inflammatory rheumatic diseases in the late 1980s
(Figure 1). The major advantage of methotrexate and
related compounds (collectively termed disease-modifying
anti-rheumatic drugs or DMARDs) was that they signifi-
cantly delayed the progression of the diseases. Although
methotrexate still remains the first line therapy for inflam-
matory rheumatic diseases, its cytotoxic (for example,
hepatotoxic) nature and/or partial efficacy limit its use.
All of the above therapeutics were developed using
an empirical approach without detailed understanding
of their mechanism of action and therapeutic targets.
However, the last decades have witnessed an explosion
of our understanding of the inflammatory process and
the molecular pathways involved. This led to a new
approach of drug development whereby targeted therap-
ies are developed by directly targeting molecules thought
to be involved in the inflammatory process. A major
approach for the development of targeted therapeutics
has been the application of monoclonal antibody technolo-
gies for therapeutic purposes.
The first targeted therapeutics in immune mediated dis-
eases were antibodies and related molecules interfering with
the function of tumor necrosis factor-α (TNF-α or TNF),
a major cytokine involved in various aspects of the
autoimmune and inflammatory process [1]. The first TNF-
antagonists against inflammatory diseases were infliximab
(first approved for the therapy of Crohn’s disease) and eta-
nercept (first approved for rheumatoid arthritis), both of
them receiving marketing authorization in 1998 (Figure 1).
Infliximab, as well as adalimumab, a third agent targeting
the TNF-α cytokine, were later also approved for rheuma-
toid arthritis. Given the biologic, rather than chemical
origin of these molecules, they have been termed biologic
therapeutics. The major advance made by biologic agents
was recognized by the 2003 Lasker award in clinical medi-
cine given to Marc Feldmann and Ravinder Maini for ‘the
discovery of anti-TNF therapy as an effective treatment
for rheumatoid arthritis and other autoimmune diseases’
All of the above three drugs are proteinaceous molecules
with antibody-related features. However, while infliximaband adalimumab are true monoclonal antibodies (infliximab
is an engineered humanized mouse monoclonal antibody
whereas adalimumab is a fully human antibody), etanercept
is a fusion protein of the Fc region of a human immuno-
globulin G (IgG) antibody linked to the extracellular
portion of the human p75 TNF-receptor.
The initial advance with anti-TNF biologic therapeutics
opened up new avenues for targeting other proinflammatory
targets by biologic agents (Figure 1). Currently approved
biologic agents for the treatment of rheumatoid arthritis
include rituximab, a chimeric antibody targeting the CD20
receptor and, thus, leading to B-cell depletion; tocilizumab,
a humanized mouse monoclonal antibody against IL-6;
abatacept, a T-cell-blocking Fc-fusion protein of the extra-
cellular domain of CTLA-4; and anakinra, an IL-1 receptor
antagonist blocking the IL-1 receptor pathway [2]. There
are also a large number of other biologic agents currently
in advanced clinical trials for the therapy of rheumatoid
arthritis [2,3] and other immune mediated diseases.
The fact that all of the above biologic agents are of a
proteinaceous nature (mainly antibodies or antibody-related
molecules) determines several important features, such as
route of administration, half-life, localization of the target,
manufacturing standards, and so on (Table 1). Therefore,
despite their rather different therapeutic targets, these bio-
logic agents are considered a unique group of therapeutics
in rheumatology.
During the last few years, an entirely different direction
for developing novel anti-inflammatory agents has emerged.
This was mainly driven by the tremendous success of
targeting intracellular tyrosine kinases in cancer ther-
apy. One of the prime examples of a breakthrough in
oncology was the development of imatinib, an inhibitor
of the Abl tyrosine kinase, for the targeted therapy of
chronic myelogenous leukemia (Figure 1), a disease caused
by the emergence of the BCR-Abl fusion protein through
a unique chromosomal translocation [4]. Additional kinase
inhibitors have also proved to provide significant clinical
benefit in solid tumors [5]. Those developments also
generated a vast experience with therapeutic targeting of
intracellular kinases. However, kinases are not only involved
in malignant processes but they also play critical roles
in non-malignant (for example, inflammatory) diseases
Table 1 Key characteristics of biologics versus small molecules
Biologics Small molecules
Chemical composition Protein Organic small molecule
Structure Known sequence, variable three-dimensional structure and glycosylation Well-defined structure
Molecular weight >1 kDa <700 Da
Stability Protease and heat-sensitive Mostly stable
Administration Parenteral Oral
In vivo half-life (Usually) Long (Usually) Short
Target Extracellular Intracellular
Mechanism of action (Usually) Blocking, depletion (Usually) Enzyme inhibition
Specificity High Low/variable
Manufacturing cost High Low/variable
Degradation Catabolism Metabolism
Generics Biosimilar Identical
The table highlights selected typical key characterisitics of biologic therapeutics and small-molecule anti-rheumatic agents. Specific drugs may deviate from the
typical features. Further differences, such as costs and standards of manufacturing, regulatory requirements, registration path, supply chain logistics, and so on
have been omitted.
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nases [7], the Syk tyrosine kinase [8] or Src-family kinases
[9], are also critically involved in immunological processes
leading to the development of autoimmune diseases. This
has led to the development of small-molecule inhibi-
tors against various protein and lipid kinases for the
treatment of autoimmune and inflammatory diseases.
One of the first kinase inhibitors to be developed for
rheumatoid arthritis was tofacitinib, a highly selective
inhibitor for Jak-family kinases, intracellular molecules
involved in signal transduction by various cytokine re-
ceptors [7]. Tofacitinib was approved by the Food and
Drug Administration (FDA) for the treatment of rheuma-
toid arthritis in late 2012 (Figure 1), as the first oral
anti-rheumatic therapy since the era of biologic agents
[10]. Fostamatinib, an inhibitor of the Syk tyrosine kin-
ase which is involved in signaling by various receptors
on hematopoietic lineage cells [8], also showed promis-
ing therapeutic effects in Phase IIb clinical trials [11]
although its further clinical development is in question
due to disappointing Phase III trials. Despite initial en-
thusiasm, targeting the p38 MAP kinase pathway did
not prove to be a viable therapeutic option in rheumatoid
arthritis [12]. In addition, a number of other small molecule
anti-rheumatic agents are in advanced clinical trials for
the treatment of rheumatoid arthritis [13]. Although
kinase inhibitors are among the most widely explored
anti-inflammatory drug candidates, small molecules acting
on non-kinase targets such as calcineurin, mTOR, adeno-
sine receptors or ion channels may also provide significant
therapeutic benefit.
While a vast knowledge on biologic agents has been
obtained during the last 15 years, we are just beginningto collect significant clinical experience with small-
molecule kinase inhibitors. It is already clear that small-
molecule inhibitors have their own unique features related
to targets, route of administration, specificity or manu-
facturing, all of which are quite different from biologic
therapeutics (Table 1). Nevertheless, both groups have
major benefits and the outcome of their long-term
comparison will be one of the most exciting questions
of clinical rheumatology in the next several years.
Discussion
Beneficial aspects of biologic therapies
Biologic therapies have successfully been introduced into
the treatment of several inflammatory rheumatic diseases,
including rheumatoid arthritis (RA), ankylosing spondylitis
(AS), psoriatic arthritis (PsA), SLE, juvenile idiopathic
arthritis (JIA), osteoporosis and ANCA-associated vasculitis.
Currently, monoclonal antibodies or fusion proteins target-
ing TNF-α, interleukin-6 receptor (IL-6R), B-lymphocytes
(the CD20 cell surface marker), interleukin-1 (IL-1), B-
lymphocyte stimulator (BLyS), and CD28-CD80/CD86
co-stimulation have been registered for the treatment of
patients with inflammatory rheumatic diseases refrac-
tory to conventional immunosuppressive treatment, and
the list of promising targets and new indications seems
to be growing rapidly [2,3].
Established long-term efficacy
A key argument in favor of biologics is their outstanding
efficacy that has revolutionized the treatment of the above-
mentioned diseases, leading to novel treatment paradigms.
Every novel anti-rheumatic drug is benchmarked against
the high standards set by biologics.
Table 2 The use of Jak-family kinases by cytokines and
other intercellular mediators
Ligand Jak-kinase
IL-6, IL-11, CNTF, CT-1, LIF, OSM, IL-27
(EBI3 + p28), IL-31, IL-35 (p35 + EBI3)
Jak1, Jak2, Tyk2
G-CSF, IL-12 (p40 + p35), angiotensin Jak2, Tyk2
Leptin, GM-CSF, IL-5, IL-3, IL-23 (p40 + p19),
serotonin, α-thrombin
Jak2
Chemokines Jak2, Jak3
IL-2 Jak1, Jak2, Jak3
IL-4, IL-9, IL-7, IL-15, IL-21 Jak1, Jak3
IL-13 Jak1, Jak2, Tyk2
IL-19, IL-20 Jak1, ?
IL-22, IL-26, IL-28A, IL-28B, IL-29,
interferon (IFNα/β), IL-10
Jak1, Tyk2
IL-24 Jak1, ?
GH, Epo Jak2
Thrombopoetin Jak2, Tyk2
IFN-γ, PDGF Jak1, Jak2
TLSP Jak1, possibly Jak2
EGF Jak1
Substances that may be involved in off-target effects of Jak-family inhibitors
are highlighted in bold. CNTF, ciliary neurotrophic factor; CT-1, cardiotrophin-1;
EGF, epidermal growth factor; Epo, erythropoietin; G-CSF, granulocyte colony
stimulating factor; GH, growth hormone; GM-CSF, granulocyte-macrophage
colony stimulating factor; IL, interleukin; LIF, leukemia inhibitory factor; OSM,
oncostatin-M; PDGF, platelet-derived growth factor; TLSP, thymic
stromal lymphopoietin.
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activity of RA, AS or PsA in the majority of the patients
compared with conventional DMARDs [14,15], although
the benefits become evident only when the biologic is com-
bined with methotrexate, apart from the IL-6R blocker
tocilizumab, which appears to be superior to methotrexate
even in monotherapy [16]. As many as 40% of the anti-
TNF-treated patients can reach a complete remission of the
disease, and the benefits of the drugs persist at least as long
as five years in the majority of the patients [15]. Long-term
remission and even drug-free remission has become a
reality in selected patients, especially if the active treatment
is started early in the disease course [17]. Consequently,
treatment guidelines and diagnostic criteria have recently
been updated in order to facilitate early diagnosis and
tight control of disease activity [18]. In addition, biologics
have been consistently found to reduce, or often halt, the
radiographic progression of RA, to preserve the functional
status of the involved joints, to reduce fatigue, to control
extra-articular manifestations (including accelerated athero-
sclerosis, the major cause of death in RA patients) and to
enable the patients to preserve their ability to work. As all
these benefits have been proven to persist during several
years of follow-up, the cost-effectiveness of these otherwise
expensive drugs has been calculated as acceptable.
Biologics are highly selective for their target molecules
The therapeutic effect of biologics relies on highly spe-
cific protein-protein interactions and, therefore, they are
highly selective for their targets. It has been emphasized
that specific targeting of a single molecule that has a key
pathogenic role in a particular disease increases the effi-
cacy of the drug and reduces the risk of side effects. Oral
Jak inhibitors, on the other hand, have multiple targets,
as listed in Table 2. Tofacitinib has been shown to
block Jak1, Jak3 and, to a lesser extent, Jak2 [19]. While
a balanced blockade of several cytokines listed in Table 2
may prove to be beneficial, the activity of a number of other
biologically active agents is also modulated by tofacitinib
(Table 2). These include haematopoietic factors, growth
hormone and growth factors, and substances interfering
with lipid metabolism, energy homeostasis, vasoregulation
and haemostasis. Some of these interferences (for example,
anemia) may have clinical consequences as indicated by
data from randomized clinical trials using tofacitinib in
which neutropenia and anemia (usually mild) occurred
more often in the tofacitinib-treated patients than in the
placebo group [20]. These effects, likely related to the broad
targeting of Jaks, require clinical monitoring. In addition
to adverse effects related to other biological functions of
the primary targets (for example, Jak kinases), off-target
effects may also represent a major problem for small-
molecule inhibitors. There are, however, strategies that
may predict off-target effects in an early phase of drugdevelopment, such as genome-wide transcriptome ana-
lysis, other in vitro and in vivo assays or new design of
future clinical trials [21-23].
Of note, anemia was also more common in the
adalimumab-treated subjects [24]. Clinically significant
neutropenia and associated infection are rare with anti-
TNF therapies and also with rituximab, but the regular
control of blood count is advisable. In contrast, neutropenia
occurs relatively frequently during the IL-6R blocker ther-
apy (with a frequency of 29% and 33% in two randomized
controlled trials (RCTs) [16,25], but high-grade neutropenia
or significant infectious events are rare. Hemoglobin levels
typically normalize quickly after the initiation of anti-TNF
therapy, and even faster during tocilizumab treatment.
Beneficial cardiovascular effects of biologics
Anti-TNF agents have proven to reduce all-cause cardio-
vascular morbidity and mortality [26]. This effect is likely
linked to changes in lipid metabolism; however, its mech-
anism is currently not fully understood. Total cholesterol,
as well as both low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) levels typically decrease during
an active inflammatory process in rheumatoid arthritis,
but rise again once the acute phase response is suppressed
by an effective therapy [27]. In this context, lipid levels
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levels, a widely used marker of acute phase response.
In fact, a persistently elevated CRP level has been
found to closely correlate with cardiovascular risk, and
the normalization of CRP in response to therapy is an
indicator of lower atherogenic risk. Some investigators
have found levels of LDL to rise and HDL to decrease
during infliximab therapy [28], a phenomenon called the
‘lipid paradox’ (indicating reduced cardiovascular risk des-
pite an increased LDL to HDL ratio) [27], whereas others
have demonstrated that HDL levels and the atherogenic
index are unchanged. More detailed analyses have revealed
that the Apo B/A-I ratio improves and macrophage
inhibitory factor levels decrease during adalimumab
treatment, and that the capacity of HDL to block the oxi-
dation of LDL and paraoxonase-1 activity increases during
anti-TNF therapy [29]. All of these findings support the
beneficial effects of anti-TNF treatment on lipid metab-
olism and atherosclerotic risk.
TNF-α is also known to cause endothelial activation,
including the up-regulation of adhesion molecules, and
it increases the production of coagulation factors and
enhances platelet activation [30]. Endothelial dysfunction
is seen as a major pathogenic factor in RA-associated car-
diovascular morbidity with an important role for TNF-α
[31,32]. TNF-α also contributes to insulin resistance, a
phenomenon that occurs more often in RA patients than
in matched healthy subjects or osteoarthritis patients [33].
Both tocilizumab, a biologic agent targeting IL-6, and the
small molecule tofacitinib have been shown to significantly
affect total cholesterol, LDL and HDL levels, although
the overall effect on cardiovascular risk has yet to be de-
termined [24,34,35]. Findings suggest that tocilizumab
could improve the arterial stiffness with comparable efficacy
to anti-TNF agents; however, the net effect of tocilizumab
and tofacitinib on long-term cardiovascular morbidity has
yet to be elucidated.
Suitability for renal or hepatic impaired patients
Biologic therapies can be administered in patients with ser-
iously impaired renal function. No differences have been
found in the pharmacokinetics of etanercept between pa-
tients on hemodialysis and those with normal renal function.
Obviously, these agents are not removed by hemodialysis or
peritoneal dialysis, and, consequently, they have been found
to be safe and effective in these patients [36]. In contrast,
there are no such data available for novel small molecules,
such as tofacitinib, in patients with severe renal failure. The
dose of tofacitinib must be reduced in patients with moder-
ate renal insufficiency according to the current FDA label. A
proportion of patients with impaired renal function may not
be appropriate candidates for Jak-inhibitor therapy.
Liver enzyme elevations (>3× upper limit of normal) were
more common with tofacitinib than with adalimumabtherapy [20]. Abnormal liver function is not a contraindica-
tion to anti-TNF or rituximab treatment, and hepatic en-
zyme elevation is rare, usually mild and transient during
these therapies. In contrast, the dose of tocilizumab should
be reduced in patients with moderate liver enzyme eleva-
tion, and the drug is not recommended for patients with se-
vere hepatic impairment according to the FDA label. It
should be noted that similar restrictions apply to the use of
the IL-6R blocker tocilizumab, as this agent also causes liver
enzyme elevations in a significant proportion of patients.
Intravenous infusion ensures maximum compliance
It has been stressed that one potential advantage of small
molecules is their oral administration route; however,
arguments may also favor parenteral administration.
Studies comparing intravenous and oral bisphosphonate
anti-osteoporotic regimens have suggested a poorer com-
pliance with once weekly oral administration as compared
with a tri-monthly or yearly intravenous route, which may
partly be responsible for the lower efficacy of the oral
agents [37]. A better compliance may be expected with
injected therapies than with twice daily tablets in a certain
proportion of patients. Apart from compliance, parenteral
administration of methotrexate has been shown not only
to cause fewer gastrointestinal adverse effects but also to
have higher efficacy and a faster onset of action [38].
Biologics may be well suited for individualized therapy
As RA and most of the autoimmune rheumatic diseases
are also of a heterogeneous nature in terms of therapeutic
response, the identification of biomarkers with a potential
to predict the response to the particular agent is of high pri-
ority. Based on theoretical considerations, differential re-
sponses to drugs targeting one single molecule may better
identify disease subsets than a molecule with pleiotropic
activity. Several parameters have been identified with a
potential to predict response to anti-TNF or B-cell-depleting
therapies [39], and some of the identified biomarkers
(such as genetic polymorphisms or levels of autoantibodies)
may prove to be useful in the identification of patient popu-
lations with optimal response to biological therapies. How-
ever, it should be noted that truly predictive biomarkers
have so far mainly been identified for small-molecule in-
hibitors in oncology; therefore, small molecule inhibitors
may be equally well suited for the individualized therapy
of inflammatory diseases.
Beneficial aspects of small-molecule therapeutics
The introduction of biologics and substantial additional
efforts aimed at understanding autoimmunity and inflam-
mation at the molecular level has not only revolutionized
the therapy of rheumatic diseases but facilitated the iden-
tification of key pathogenic molecules in autoimmune
diseases. A better understanding of the molecular nature
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signaling pathways downstream of these receptors has
led to novel approaches to target various players in dis-
ease pathogenesis. Until recently, however, the success
of small molecule targeted therapeutic approaches in
rheumatology has not achieved the level of biologics,
mainly due to off-target toxicity (non-selectivity), inefficacy,
or unfavorable risk/benefit ratios. This is in contrast to the
experience in cancer therapy where small molecule-based
targeted therapies (such as BCR-Abl inhibitors) have been
used successfully for the treatment of chronic myeloid
leukemia and other hematological malignancies.
How can small molecules contribute to the therapeutic
armamentarium of rheumatic diseases that is currently
dominated by biologics? For this, one should take into
account the key differences between small molecules
and biologics (Table 1). In particular, small molecules: 1)
are typically administered orally; 2) have a higher likeli-
hood for off-target effects (based on non-selectivity); and
3) have the ability to directly target intracellular signaling
pathways. This section reviews these three key points
to underscore why novel small molecules may also have a
promising future in rheumatology.
Oral administration is a major advantage for small molecules
Despite the outstanding efficacy and good safety/tolerability
profile of the currently used biologics in rheumatology, the
requirement for long-term injections or infusions can
impose a burden on patients leading to reduced adher-
ence. Needle phobia is not uncommon: twenty-two percent
of participants in the general population reported a fear
of needles in a recent survey [40]. In multiple sclerosis,
for which no effective oral treatment was available until
recently, injection anxiety or needle phobia could prevent
patients from self-injecting their biologics [41]. Misunder-
standing about the risks of self-injection or a lack of know-
ledge about how best to manage injection pain and side
effects may also result in an inability to self-inject [41].
Advances in injection technology, such as the introduction
of auto-injectors have improved patient satisfaction and re-
duced the incidence of injection-site reactions; however, pa-
tients’ resistance to self-injection still exists [41]. According
to the RAISE (Rheumatoid Arthritis: Insights, Strategies and
Expectations, 2009) survey, about 25% of survey participants
with RA currently treated with a subcutaneous injection rely
on caregivers or healthcare providers to administer the
medication, and 24% of patients who self-inject experience
pain upon injection and 20% experience irritation at the in-
jection site [42]. Injection-site reactions or patients’ negative
feelings towards any therapy administered via needles may
negatively affect patient acceptance of treatment and often
result in non-compliance.
Non-adherence to a treatment regimen is a prevalent
and major problem of patients with chronic disorders.Approximately half of the patients with a chronic disease
have problems following their prescribed regimen to the ex-
tent that they are unable to obtain the desired clinical bene-
fit, and poor adherence attenuates optimal clinical benefit
[43]. The World Health Organization has recognized the
lack of adherence as a major problem in the management
of chronic diseases and concluded that improving adher-
ence would have an even more beneficial effect on health
outcome than improving the efficacy of specific treatments
[44]. It is often assumed that the population is generally
adherent but in many chronic conditions, on average, only
about half of the patients comply with care recommenda-
tions over the long term [45].
Overall, oral therapies with new modes of action have
the potential to expand the current treatment repertoire,
increase patient satisfaction and adherence, and thereby
improve efficacy. Patients express greater satisfaction with
the convenience of oral therapies, and oral medications
are known to be preferred to injected therapies that have
similar efficacy. Thus, treatment efficacy can be improved
simply through its effect on adherence.
Broader target selectivity can be of therapeutic benefit for
small molecules
The experience in cancer therapy established the principle
that kinase inhibitors do not need to be absolutely specific
to be clinically useful; off-target effects may even be
therapeutically beneficial. The competitive inhibition of the
BCR-Abl tyrosine kinase leads to inhibition of proliferation,
restoration of cell cycle control, induction of apoptosis and
reversal of genetic instability in BCR-Abl dependent
cells in vitro [46]. Based on this mode of action, BCR-Abl
inhibitors such as imatinib or next generation sunitinib,
dasatinib and nilotinib can induce remission in more than
90% of patients in the early stages of chronic myelogenous
leukemia (CML). Imatinib, however, is not selective for
BCR-Abl and also inhibits the PDGFR kinase and KIT
receptor tyrosine kinase, thereby expanding its therapeutic
utility to other diseases, for example, gastrointestinal stro-
mal tumors [47] or idiopathic hypereosinophilic syndrome
[48]. In addition, the effect of dasatinib is likely, at least in
part, mediated by its inhibitory effect on Src-family kinases.
Further potential benefit of broad(er) targeting may be the
simultaneous modulation of several cytokine pathways
in the same disease (for example, by Jak inhibition in RA)
exerting a stronger therapeutic effect (Table 2).
Small molecules are often associated with adverse
reactions due to off-target effects. However, biologics
with very high specificity can also cause severe adverse
events. For example, an increased risk of serious tu-
berculosis and other opportunistic infections has been
reported with TNF-blocking agents across various studies,
and that effect is likely directly related to the target
molecule [49]. In addition, the effect of certain biologics
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depleting the cellular lineage expressing the target molecule;
in that case, a wider functional consequence of biological
therapy is expected. Small-molecule Jak inhibitors have
been shown to adversely impact serum lipid profiles;
however, pro-atherogenic lipid changes and decreased
hepatic LDL receptor expression were also demonstrated
with tocilizumab in RA [34]. The net effect of these drugs
on morbidity and mortality has to be confirmed in future
long term clinical trials regardless of whether it is related
to on- or off-target effects.
Overall, for the patient and treating physician, the risk/
benefit will be determined by both off-target and on-target
effects and is based on safety and efficacy – regardless of
target selectivity.
Inhibiting intracellular signaling may be as effective as
targeting specific cell surface receptors
Inhibition of intracellular signaling molecules operating at
critical nodes of pathways has always been an attractive ap-
proach to achieve a high magnitude and/or robust duration
of therapeutic response in inflammatory immune mediated
diseases [50]. Small molecules can directly target such
intracellular pathways for which a large variety of candidate
molecules exists; of those, kinases still remain the most
attractive targets in rheumatology. Just as the biologic
era came about as a consequence of major advances in
protein engineering to allow the production of antibodies
or engineered derivatives, advances in medicinal chemistry
in the past two decades have also enabled the otherwise
challenging development of very specific kinase inhibitors
as therapeutic agents.
Kinases catalyze reversible phosphorylation, a fundamen-
tal mechanism for the regulation of protein function in vari-
ous receptor-mediated processes, such as cell growth and
differentiation in eukaryotic cells [51]. Many key immune
receptors, including those responsible for driving inflamma-
tion, exert their effects through kinases and phosphorylation
events. The human kinome comprises a total of 518 kinases
and a large fraction of those functions downstream of cyto-
kine, antigen and Fc-receptors, all representing potential
targets for the treatment of rheumatic diseases.
More than 60 cytokines signal via the Janus kinase
(Jak) and signal transducer and activator of transcription
(STAT) pathways. Jak inhibitors have now been approved
for the treatment of immune-mediated diseases, such as
RA and myelofibrosis, and various Jak inhibitors are being
developed and tested in a wide range of autoimmune dis-
eases [52]. Although long term safety and efficacy data are
not yet available for these inhibitors, the short term effi-
cacy of tofacitinib, a Jak inhibitor in RA seems to be com-
parable to that of anti-TNF agents while side effects, such
as infection, anemia and neutropenia, appear to be directly
related to its mode of action [53].Beyond Jaks, spleen tyrosine kinase (Syk) and Bruton
tyrosine kinase (Btk) are also critical enzymes in the sig-
naling pathways activated by immunological receptors in-
volved in B and T cell function [50]. Kinases downstream
of antigen and Fc-receptors also represent novel targets
including members of the protein kinase C (PKC) family,
mitogen-activated protein kinase (MAPK) family, the lipid
kinase phosphoinositide 3-kinase (PI3K), protein kinase B
(PKB, also known as Akt) and mammalian target of rapa-
mycin (mTOR). Inhibitors of these proteins are currently
being tested in preclinical models or clinical trials of vari-
ous immune-mediated diseases [50]. Development of oral
inhibitors of Jak and Syk are the most advanced and have
already demonstrated clinical efficacy in RA.
Furthermore, not only kinases can be targeted by oral
immune modulators. Examples include early studies in
RA with a sphingosine-1-phosphate lyase inhibitor to
modulate lymphocyte redistribution, or with the chemokine
receptor-1 antagonist involved in osteoclast maturation,
mobility and activation [54].
Given the large number of key effector proteins dis-
covered in a wide variety of cell functions, together
with the growing scientific understanding of the patho-
genesis of immune mediated diseases, further small
molecule based targeted immunomodulators will likely
emerge in the near future.
Additional potential benefits of small molecules
Biologic agents and small molecules usually differ in their
half-life, as well. Protein-like biologics currently used or
tested in rheumatology usually have a longer half-life than
small molecules. While such biologics require less frequent
administration, they also need longer elimination; in cases
where fast elimination is desirable, for example, during in-
fections or before surgical interventions, the short half-life
of small molecules may be of considerable clinical benefit.
Beyond the medical aspects, there are other factors that
may have a positive effect on the overall cost-effectiveness
of small molecules. Although it is too early to speculate
about the long-term costs of small molecules, should
these agents (requiring less complex and less expensive
manufacturing) be significantly less expensive than bio-
logics, this would certainly add significant value to the use
of small molecules. Some small molecule drugs are also
advantageous in terms of several logistical aspects, such as
longer shelf life, no need for refrigeration and easier distri-
bution in rural areas where infrastructure/experience with
parenteral administration is limited.
Summary
After a revolution in rheumatology by biologic therapy,
novel intracellular targets have also emerged from an
improved understanding of the immunopathogenesis
of inflammatory rheumatic diseases. While biologics can
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cellular processes can be more effectively targeted by
small molecules. As a result, a number of small-molecule
anti-rheumatic agents have been developed and many
of those have progressed to preclinical stages or human
clinical studies. As compared to biologics, small mole-
cules also differ in the route of administration, target
selectivity and specificity in terms of safety and efficacy
as well as development path and overall cost. Despite such
major advances in rheumatology, still no ideal treatment
exists as current therapies are not causal and no single
monotherapy, either small molecule or biologic, is capable
of inducing full remission in the majority of patients in
most rheumatic diseases. True synergies exist when both
classic small molecule approaches and protein therapeutic
strategies are simultaneously applied. Combination ther-
apy likely continues to be a key therapeutic approach for
most rheumatic diseases.
Currently, several novel approaches with biologics as
well as small molecules are being tested to target various
immunopathogenic players in immune-mediated rheum-
atic diseases. In addition to the existing effective biologic
agents, highly effective oral drugs also seem to emerge.
The next several years will witness a real-life comparison
of the clinical efficacy and safety of biologics and oral
therapies in rheumatology and provide the answers eagerly
awaited by the rheumatology community.
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